Atlas Trials

Study of Anlotinib Plus Chemotherapy as the First-line Treatment in Patients With Advanced NSCLC

Clinical trial NCT03636685 · UNKNOWN

Trial details

NCT number
NCT03636685
Sponsor
Chinese Academy of Medical Sciences
Status
UNKNOWN
Phase
Phase 1, Phase 2
Study type
INTERVENTIONAL
NSCLCAdenocarcinomaSquamous Cell Carcinoma
Start date
2018-08-15
Primary completion
2019-08-14
Enrollment
60

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.